Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | COVID-19 | Research

Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China

Authors: Yanhai Wang, Guohui Yu, Jingru Shi, Xiaqing Zhang, Jianxin Huo, Meng Li, Jiaxi Chen, Liyuan Yu, Yan Li, Zhiliang Han, Jianwen Zhang, Xuna Ren, Yujie Wang, Wu Yuntana

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Fear of a global public health issue and fresh infection wave in the persistent COVID-19 pandemic has been enflamed by the appearance of the novel variant Omicron BF.7 lineage. Recently, it has been seeing the novel Omicron subtype BF.7 lineage has sprawled exponentially in Hohhot. More than anything, risk stratification is significant to ascertain patients infected with COVID-19 who the most need in-hospital or in-home management. The study intends to understand the clinical severity and epidemiological characteristics of COVID-19 Omicron subvariant BF.7. lineage via gathering and analyzing the cases with Omicron subvariant in Hohhot, Inner Mongolia.

Methods

Based upon this, we linked variant Omicron BF.7 individual-level information including sex, age, symptom, underlying conditions and vaccination record. Further, we divided the cases into various groups and assessed the severity of patients according to the symptoms of patients with COVID-19. Clinical indicators and data might help to predict disadvantage outcomes and progression among Omicron BF.7 patients.

Results

In this study, in patients with severe symptoms, some indicators from real world data such as white blood cells, AST, ALT and CRE in patients with Omicron BF.7 in severe symptoms were significantly higher than mild and asymptomatic patients, while some indicators were significantly lower.

Conclusions

Above results suggested that the indicators were associated with ponderance of clinical symptoms. Our survey emphasized the value of timely investigations of clinical data obtained by systemic study to acquire detailed information.
Appendix
Available only for authorised users
Literature
1.
Singh JK, Anand S, Srivastava SK. Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant. Int J Biol Macromol. 2023;238:124154.PubMedPubMedCentralCrossRef
2.
Wang X, Ouyang M, Carcel C, et al. Impact of COVID-19 on stroke services in China: survey from the Chinese Stroke Association. Stroke Vasc Neurol. 2020;5(4):323–30.PubMedPubMedCentralCrossRef
3.
Akif A, Bhuiyan MA, Islam MR. SARS-COV-2 Omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do? J Med Virol. 2023;95(2):e28551.PubMedCrossRef
4.
Dhama K, Tuglo LS, Chakraborty C, et al. BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies. Int J Surg. 2023;109(4):1058–9.PubMedPubMedCentralCrossRef
5.
Ding Y, Fan F, Xu X, et al. A COVID-19 DNA vaccine candidate elicits broadly neutralizing antibodies against multiple SARS-CoV-2 Variants including the currently circulating Omicron BA.5, BF.7, BQ.1 and XBB. Vaccines (Basel). 2023;11(4):778.PubMedCrossRef
6.
Dognon N, Gaudet A, Parmentier-Decrucq E, et al. Extracorporeal membrane oxygenation for COVID 2019-acute respiratory distress syndrome: comparison between first and second waves (Stage 2). J Clin Med. 2021;10(21):4839.PubMedPubMedCentralCrossRef
7.
Elnour AA, Don J, Yousif I, et al. The early mortality rate of people infected with coronavirus (COVID-19) in Wuhan, China: review of three retrospective studies. J Pharm Bioallied Sci. 2020;12(3):223–33.PubMedPubMedCentralCrossRef
8.
9.
Ghosh S, Shree A. Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: a correspondence. New Microbes New Infect. 2023;52:101089.PubMedPubMedCentralCrossRef
10.
Hinduja RH, George K, Barthwal M, et al. Radiation oncology in times of COVID-19: A review article for those in the eye of the storm - an Indian perspective. Semin Oncol. 2020;47(5):315–27.PubMedPubMedCentralCrossRef
11.
Jin P, Li J, Pan H, et al. Immunological surrogate endpoints of COVID-19 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):48.PubMedPubMedCentralCrossRef
12.
Lejeune JA, Sikov J, Loubeau JK, et al. The toll of COVID-19 on diverse, urban children with attention deficit hyperactivity disorder and their families: a case series. Clin Pediatr (Phila). 2022;61(3):222–7.PubMedCrossRef
13.
Migliorini F, Weber CD, Pappalardo G, et al. Orthopaedic, trauma surgery, and COVID-19 pandemic: clinical panorama and future prospective in Europe. Eur J Trauma Emerg Surg. 2022;48(6):4385–402.PubMedPubMedCentralCrossRef
14.
Salami VU, Okoduwa SIR, Chris AO, et al. Opinion Review of Socioeconomic Impact of COVID-19 on Women’s Health. Front Glob Womens Health. 2021;2:647421.PubMedPubMedCentralCrossRef
15.
16.
Gao X, Wang F, Liu H, et al. BF.7: a new Omicron subvariant characterized by rapid transmission. Clin Microbiol Infect. 2024;30(1):137–41.
17.
18.
Chenchula S, Amerneni KC, Ghanta MK, et al. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 Omicron sub variant BF.7 (BA.5.2.1.7): a systematic review. Virology. 2023;584:38–43.PubMedCrossRef
19.
Scarpa F, Giovanetti M, Azzena I, et al. Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia. J Med Virol. 2023;95(4):e28714.PubMedCrossRef
20.
Nazmunnahar, Ahmed I, Islam MR. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: a brief report. Health Sci Rep. 2023;6(3):e1127.PubMedPubMedCentralCrossRef
21.
Kelleni MT. Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB1.5: time to follow Africa and abort all COVID restrictions. J Infect. 2023;86(4):405.PubMedPubMedCentralCrossRef
22.
Leung K, Lau EHY, Wong CKH, et al. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022. Nat Med. 2023;29(3):579–82.PubMedCrossRef
23.
24.
Mohapatra RK, Mahal A, Mishra S, et al. Possible threat of the Omicron subvariant BF.7 to FIH Hockey World Cup 2023 in particular and the South-East Asia Region in general. Int J Surg. 2023;109(3):646–7.PubMedPubMedCentralCrossRef
25.
Rahman MM, Akash S, Islam MR. SARS-CoV-2 new variant BF.7: a new public threat globally, symptoms, precautions, transmission rate, and futures perspective – correspondence. Int J Surg. 2023;109(2):181–3.PubMedPubMedCentralCrossRef
26.
Zhang Z, et al. Diagnosis and treatment protocol for COVID‐19 patients (Tentative 10th Version). Health Care Science. 2023;2(1):10–24.
27.
28.
29.
30.
Khullar N, Bhatti JS, Singh S, et al. Insight into the liver dysfunction in COVID-19 patients: molecular mechanisms and possible therapeutic strategies. World J Gastroenterol. 2023;29(14):2064–77.PubMedPubMedCentralCrossRef
31.
Miranda C, Garlatti E, da Porto A, et al. Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update. Arch Med Sci Atheroscler Dis. 2023;8:e1–10.PubMedPubMedCentralCrossRef
32.
Ramouz A, Fakour S, Jafari M, et al. Surgical management of primary liver cancers during the COVID-19 pandemic: overcoming the dilemma with standardization. HPB (Oxford). 2023;25(8):907-14.
33.
Rivera-Tenorio A, Hernandez Diaz H, Triana PA, et al. Drug-induced liver injury after covid-19 mRNA vaccine: case report. Colomb Med (Cali). 2022;53(3):e5005187.PubMed
34.
Sigurdarson J, Eythorsson E, Bjarnason A, et al. Liver injury in patients with COVID-19 in comparison to patients with the pandemic influenza A (H1N1) 2009: a population-based study. Scand J Gastroenterol. 2023;58(10):1145-52.
35.
Wang RX, Abu-Gazala S, Mahmud N. Post-transplant outcomes and trends in utilization of covid-19 positive deceased donor liver transplantation. Liver Transpl. 2023;29:1129.PubMedCrossRef
36.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.PubMedCrossRef
37.
Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161–76.PubMedCrossRef
38.
Bowe B, Cai M, Xie Y, et al. Acute kidney injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clin J Am Soc Nephrol. 2020;16(1):14–25.PubMedPubMedCentralCrossRef
39.
40.
Silva BM, Assis LCS, Batista Junior MC, et al. Acute kidney injury outcomes in covid-19 patients: systematic review and meta-analysis. J Bras Nefrol. 2022;44(4):543–56.PubMedPubMedCentral
41.
42.
Wang W, Wang SI, Wei JC. Response to: ’Concerns about “Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks” by Renin Chang et al. EClinicalMedicine. 2022;53:101700.PubMedPubMedCentralCrossRef
43.
Wang W, Wang CY, Wang SI, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619.PubMedPubMedCentralCrossRef
44.
Chang R, Sun CK, Hung YM. Concerns about Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101701.PubMedPubMedCentralCrossRef
45.
Chakraborty A, Johnson JN, Spagnoli J, et al. Long-term cardiovascular outcomes of multisystem inflammatory syndrome in children associated with COVID-19 using an institution based algorithm. Pediatr Cardiol. 2023;44(2):367–80.PubMedCrossRef
46.
Motloch LJ, Jirak P, Mirna M, et al. Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. Front Cardiovasc Med. 2022;9:916156.
47.
Yang L, Zhong J, Wang W, et al. Clinical features of Omicron variant infection in 445 patients with coronavirus 19 disease. Ann Saudi Med. 2023:1–5.
48.
Bloomfield LE, Ngeh S, Cadby G, et al. SARS-CoV-2 vaccine effectiveness against Omicron variant in infection-naive population, Australia, 2022. Emerg Infect Dis. 2023;29(6):1162.PubMedPubMedCentralCrossRef
49.
Chang H, Li J. “Lymphocyte * Neutrophil” count decreased in SARS-CoV-2 Omicron patients in Shanghai with no significant change in CRP and SAA. J Clin Lab Anal. 2022;36(10):e24671.PubMedPubMedCentralCrossRef
50.
Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-77.e3.PubMedPubMedCentralCrossRef
51.
Xu CC, Ruan XZ, Chen XQ, et al. CT-based staging and prognosis of novel coronavirus (COVID-19) pneumonia: correlation with blood glucose levels. Eur Rev Med Pharmacol Sci. 2020;24(24):13056–61.PubMed
52.
Chertok Shacham E, Maman N, Ishay A. Blood glucose control with different treatment regimens in type 2 diabetes patients hospitalized with COVID-19 infection: a retrospective study. Medicine (Baltimore). 2023;102(3):e32650.PubMedCrossRef
53.
Chai C, Chen K, Li S, et al. Effect of elevated fasting blood glucose level on the 1-year mortality and sequelae in hospitalized COVID-19 patients: a bidirectional cohort study. J Med Virol. 2022;94(7):3240–50.PubMedPubMedCentralCrossRef
54.
Duan W, Li L, Li X, et al. Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19. Endocrine. 2022;75(1):1–9.PubMedCrossRef
55.
Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B beta-coronaviruses, including 2019-nCoV. bioRxiv. 2020;2020.01.22.915660.
56.
Rahman A, Sarkar A. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: analyses of risk factors and literature review of knowledge, attitude and practices. Zoonoses Public Health. 2022;69(6):635–42.PubMedCrossRef
57.
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study [J]. Lancet. 2020;395(10225):689–97.PubMedPubMedCentralCrossRef
58.
Wei Y, Lu Y, Xia L, et al. Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: an epidemiological study from a fever clinic in Wuhan, China. J Med Virol. 2020;92(11):2758–67.PubMedPubMedCentralCrossRef
59.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.PubMedPubMedCentralCrossRef
60.
Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202.PubMedPubMedCentralCrossRef
61.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet. 2020;395(10223):497–506.PubMedPubMedCentralCrossRef
Metadata
Title
Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China
Authors
Yanhai Wang
Guohui Yu
Jingru Shi
Xiaqing Zhang
Jianxin Huo
Meng Li
Jiaxi Chen
Liyuan Yu
Yan Li
Zhiliang Han
Jianwen Zhang
Xuna Ren
Yujie Wang
Wu Yuntana
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09084-8

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue

Research

Diagnosis of human leptospirosis: systematic review and meta-analysis of the diagnostic accuracy of the Leptospira microscopic agglutination test, PCR targeting Lfb1, and IgM ELISA to Leptospira fainei serovar Hurstbridge

Research

Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis

Research

Prevalence of high-risk human papillomavirus genotypes in outpatient Malian women living with HIV: a pilot study

Research

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

Research

Difficult-to-treat HIV in Sweden: a cross-sectional study

Case Report

Disseminated Talaromyces marneffei infection initially presenting as cutaneous and subcutaneous lesion in an HIV-Negative renal transplant recipient: a case report and literature review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits